Medtronic Announces Partnership with BioIntelliSense for Exclusive U.S. Distribution of Multiparameter Wearable Devices for Continuous Remote Patient Monitoring from Hospital to Home

  • The partnership reflects the commitment to patient safety; BioButton® wearable device offers up to 1,440 daily vital sign measurements, monitoring patients transitioning from higher to lower acuity
  • Technology complements Medtronic Patient Monitoring’s HealthCast™ portfolio of intelligent patient managers, designed for connectivity, visualization, remote patient monitoring and now wearable devices

DUBLIN, August 31, 2022 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global health technology leader, today announced that it has entered into a strategic partnership with BioIntelliSense, a continuous health monitoring and clinical intelligence company, to the exclusive U.S. hospital and post-acute hospital-to-home distribution rights to the BioButton® multi-parameter wearable device for continuous, connected monitoring. The partnership enables Medtronic’s patient monitoring business to offer access to a medical-grade device that provides continuous measurements of vital signs for patients in general care in the hospital as well as after discharge. This supports the simplification of care delivery through workflow automation, enabling proactive clinical intervention and helping to address the implications of staffing shortages. The terms of the contract are not disclosed.

The medical-grade BioButton device, measuring up to 1,440 vital signs measurements per day, including skin temperature, resting respiratory rate and resting heart rate, is the exclusive multi-parameter wearable for activity patient monitoring. This device, combined with advanced analytics, has the potential to help clinicians better detect early signs of patient deterioration or, conversely, identify stable patients who may be candidates for earlier discharge from hospital. The rechargeable BioButton device also has configurable acute and post-acute modes to continuously monitor patients as they transition from higher to lower acuity.

“Our vision is to empower clinicians and patients with actionable insights to personalize care – anytime, anywhere,” said Frank Chan, Ph.D., president of the Patient Monitoring business, which is part of Medtronic’s medical-surgical portfolio. “Today, our solutions reach more than 100 million patients each year in hospitals. Through our collaboration with BioIntelliSense, we will support seamless, connected care from hospital to home and expand our reach to help more patients in more places than ever before.

With staff shortages expected to reach 3.2 million healthcare workers by 20261, the Patient Monitoring business intends to continue to develop its HealthCast™ portfolio to improve workflow automation so clinicians can focus on what matters most: their patients. The HealthCast™ Connectivity Gateway helps increase workflow efficiency by connecting unconnected devices to electronic medical records (EMR) and saves valuable staff time by reducing the burden of manual mapping. The HealthCast™ VitalSync™ Remote Patient Monitoring System enables clinicians to receive near real-time trending and alert data on web-enabled devices so they can act on patient deterioration earlier. With the addition of the BioButton multi-parameter wearable device to the HealthCast portfolio, Medtronic can help even more general care patients inside and outside the hospital, furthering our commitment to patient safety.

“In partnership with Medtronic, we are poised to accelerate seamless connected care models that deliver a new level of clinical oversight and workflow efficiencies for hospitals that are challenged in today’s healthcare environment. increasing labor shortages and managing the cost of care,” said James Mault, MD, Founder and CEO of BioIntelliSense. “This advanced remote physiological monitoring simplifies care delivery to facilitate personalized patient care, clinical workflow automation, and proactive clinical interventions.”

About BioIntelliSense
BioIntelliSense ushers in a new era of continuous health monitoring and clinical intelligence for remote patient monitoring (RPM). Its medical-grade data-as-a-service (DaaS) platform seamlessly captures multiparameter vital signs and physiological biometrics through an effortless patient experience. The medical grade BioButton® The devices simplify remote monitoring and early detection. With the platform’s advanced analytics, clinicians have access to high-resolution patient trends and alerts to enable medical-grade remote care from hospital to home.

Learn how BioIntelliSense is redefining remote patient monitoring with cost-effective, medical-grade data services or visit our website at Follow BioIntelliSense on Twitter and LinkedIn for the latest news and information.

About the Patient Monitoring Business at Medtronic
The Patient Monitoring business is committed to transforming the future of health monitoring. Our vision is to empower clinicians and patients with actionable insights to personalize care. Our technologies including HealthCast™ Intelligent Patient Manager, VitalSync™ Remote Patient Monitoring, Nellcor™ Pulse Oximetry, Microstream™ Capnography, BIS™ Brain Monitoring and INVOS™ Regional Oximetry are still under monitoring, helping clinicians ensure patient safety.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the global health technology leader boldly tackling the toughest health challenges facing humanity by researching and finding solutions. Our mission – to relieve pain, restore health and extend life – unites a global team of more than 95,000 passionate people in 150 countries. Our technologies and therapies address 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. With our diverse knowledge, insatiable curiosity, and desire to help everyone in need, we deliver innovative technologies that transform two people’s lives every second, every hour, every day. Expect more from us as we deliver insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we design the extraordinary. For more information about Medtronic (NYSE:MDT), visit and follow @Medtronic on Twitter and LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports filed with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Medtronic’s patient monitoring products should not be used as the sole basis for diagnosis or therapy and are intended only to supplement patient assessment.


  1. AHA.


Tammy Hudson

Ryan Weispfenning

Public relations

Investor Relations




Eric Schudiske

[email protected]

SOURCEMedtronic plc


Comments are closed.